retatrutide phase 2 results 2024 2025 The Effect of on Kidney Parameters in Participants With Type Diabetes Mellitus and/or Obesity Phase 2 trial results demonstrate

Retatrutide is being studied as a triple agonist, while tirzepatide is an approved dual agonist for certain indications

An experienced family medicine physician or NP who regularly manages obesity can prescribe retatrutide just as appropriately as an endocrinologist." Not every prescriber will be comfortable writing for an investigational compound accessed through compounding

All use subcutaneous injection

Food does not affect the absorption or efficacy of subcutaneous GLP-1 injections, so you may administer them at any time regardless of meals

They serve as an adjunct tool to support continued appetite control and metabolic health in the long term